PE20061334A1 - Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada - Google Patents

Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada

Info

Publication number
PE20061334A1
PE20061334A1 PE2005001502A PE2005001502A PE20061334A1 PE 20061334 A1 PE20061334 A1 PE 20061334A1 PE 2005001502 A PE2005001502 A PE 2005001502A PE 2005001502 A PE2005001502 A PE 2005001502A PE 20061334 A1 PE20061334 A1 PE 20061334A1
Authority
PE
Peru
Prior art keywords
solid pharmaceutical
pharmaceutical dosage
dosage forms
modified release
oral route
Prior art date
Application number
PE2005001502A
Other languages
English (en)
Inventor
Klaus Benke
Jan-Olav Henck
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36001174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061334(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20061334A1 publication Critical patent/PE20061334A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION FARMACEUTICA SOLIDA ORAL DE LIBERACION MODIFICADA QUE COMPRENDE 5-CLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORFOLINIL)FENIL]-1,3-OXAZOLIDIN-5-IL}METIL)-2-TIOFENOCARBOXAMIDA, DONDE DICHO PRINCIPIO PUEDE ENCONTRARSE EN FORMA CRISTALINA, MICRONIZADA, HIDROLIZADA O AMORFA. DICHA FORMA DE DOSIFICACION LIBERA UN 80% DEL PRINCIPIO ACTIVO DURANTE UN INTERVALO DE TIEMPO DE 2 A 24 HORAS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION. DICHA FORMA DE DOSIFICACION ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES TROMBOEMBOLICAS ARTERIALES Y/O VENOSAS
PE2005001502A 2004-12-24 2005-12-16 Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada PE20061334A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004062475A DE102004062475A1 (de) 2004-12-24 2004-12-24 Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung

Publications (1)

Publication Number Publication Date
PE20061334A1 true PE20061334A1 (es) 2007-01-28

Family

ID=36001174

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001263A PE20081189A1 (es) 2004-12-24 2005-12-16 Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada
PE2005001502A PE20061334A1 (es) 2004-12-24 2005-12-16 Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008001263A PE20081189A1 (es) 2004-12-24 2005-12-16 Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada

Country Status (32)

Country Link
US (1) US20070026065A1 (es)
EP (1) EP1830855B1 (es)
JP (1) JP5285913B2 (es)
KR (1) KR20070094631A (es)
CN (2) CN101128205A (es)
AR (1) AR052843A1 (es)
AT (1) ATE458486T1 (es)
AU (1) AU2005324132B2 (es)
BR (1) BRPI0519376A2 (es)
CA (1) CA2591972C (es)
CY (1) CY1110649T1 (es)
DE (2) DE102004062475A1 (es)
DK (1) DK1830855T3 (es)
ES (1) ES2340053T3 (es)
GT (1) GT200500384A (es)
HN (1) HN2005036387A (es)
IL (1) IL184126A0 (es)
MA (1) MA29115B1 (es)
MX (1) MX2007007491A (es)
MY (1) MY143999A (es)
NO (1) NO20073853L (es)
NZ (1) NZ556015A (es)
PE (2) PE20081189A1 (es)
PL (1) PL1830855T3 (es)
PT (1) PT1830855E (es)
RU (1) RU2420290C2 (es)
SI (1) SI1830855T1 (es)
SV (1) SV2007002359A (es)
TW (1) TW200637558A (es)
UA (1) UA88938C2 (es)
WO (1) WO2006072367A1 (es)
ZA (1) ZA200704661B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910975D0 (en) * 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
GB0116074D0 (en) * 2001-06-29 2001-08-22 Univ Strathclyde Nanoparticle structures
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
GB0300427D0 (en) * 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE502006009169D1 (en) 2005-10-04 2011-05-05 Bayer Schering Pharma Ag NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US9125833B2 (en) * 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US20100210732A1 (en) * 2005-11-02 2010-08-19 Najib Babul Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor
DE102006007146A1 (de) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
CN101420937B (zh) * 2006-04-12 2011-06-22 日本曹达株式会社 缓释性片剂的制造方法
EP2032124A1 (en) * 2006-06-27 2009-03-11 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
EP2049087A2 (en) * 2006-07-21 2009-04-22 LAB International SRL Hydrophilic abuse deterrent delivery system
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
MX2009002669A (es) * 2006-09-12 2009-03-24 Glaxo Group Ltd Composicion farmaceutica que comprende una pluralidad de mini-comprimidos que comprenden un inhibidor del factor xa.
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US20110045028A1 (en) * 2006-11-30 2011-02-24 Takeda Pharmaceutical Company Limited Sustained release preparation
GB0707938D0 (en) * 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
CN101821260B (zh) * 2007-08-14 2013-07-31 康塞特医药品有限公司 取代的噁唑烷酮衍生物
GB0724498D0 (en) * 2007-12-15 2008-01-30 Univ Strathclyde Slow release compositions
CA2729979A1 (en) * 2008-07-08 2010-01-14 Ratiopharm Gmbh Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US20110189279A1 (en) * 2008-08-11 2011-08-04 Ratiopharm Gmbh Pharmaceutical compositions with modified release properties comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US20100168111A1 (en) * 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
EP2266541A1 (en) * 2009-06-18 2010-12-29 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
DK2442799T3 (da) * 2009-06-18 2017-01-02 Krka Tovarna Zdravil D D Novo Mesto Fast farmaceutisk sammensætning omfattende rivaroxaban
EP2485715A1 (en) 2009-10-06 2012-08-15 Ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
EP2308472A1 (en) 2009-10-06 2011-04-13 ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
PT2554168T (pt) 2010-03-29 2018-02-28 Astellas Pharma Inc Composição farmacêutica de libertação controlada
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
MX2014013320A (es) 2012-05-07 2015-08-10 Bayer Pharma AG Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo.
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
GB2504076A (en) 2012-07-16 2014-01-22 Nicoventures Holdings Ltd Electronic smoking device
CN103550166A (zh) * 2013-10-31 2014-02-05 江苏阿尔法药业有限公司 一种利伐沙班口服微球制剂
CN103705520A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种利伐沙班固体组合物的制备方法
WO2015124995A1 (en) * 2014-02-19 2015-08-27 Aurobindo Pharma Ltd Solid dosage forms of rivaroxaban
CN104887633B (zh) * 2014-03-04 2019-01-29 山东新时代药业有限公司 一种利伐沙班片剂及其制备方法
KR101499867B1 (ko) * 2014-04-22 2015-03-06 에스케이케미칼주식회사 활성 성분 (i) 함유 조성물 및 이의 제조 방법
KR101535586B1 (ko) * 2014-08-01 2015-07-09 에스케이케미칼주식회사 무정형 또는 열역학적 준 안정형 리바록사반을 포함하는 약학 제제
WO2016144071A2 (ko) * 2015-03-06 2016-09-15 에스케이케미칼 주식회사 리바록사반을 포함하는 약학제제
US9989579B2 (en) * 2016-06-20 2018-06-05 Eaton Intelligent Power Limited Monitoring systems and methods for detecting thermal-mechanical strain fatigue in an electrical fuse
JP6744571B2 (ja) * 2016-06-22 2020-08-19 富士ゼロックス株式会社 情報処理装置およびプログラム
BR112019000187A2 (pt) * 2016-07-05 2019-04-24 Alphamed Formulations Pvt Ltd composição sólida contendo anticoagulante oral
GB201801655D0 (en) * 2018-02-01 2018-03-21 British American Tobacco Investments Ltd Pouches containing an aerosolisable material, a container and aerosol generating device for use therewith
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CA3107174A1 (en) 2018-07-24 2020-01-30 Bayer Aktiengesellschaft Pharmaceutical dosage form which can be administered orally and has modified release
MA53368A (fr) 2018-07-24 2021-06-02 Bayer Ag Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale
JP7305527B2 (ja) * 2018-11-30 2023-07-10 大原薬品工業株式会社 リバーロキサバンと嬌味剤を含有する固形製剤
EP4208462A1 (en) * 2020-09-05 2023-07-12 Inventia Healthcare Limited Rivaroxaban compositions
GR1010231B (el) 2021-03-24 2022-05-10 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει ριβαροξαμπανη και μεθοδος παρασκευης αυτου

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2811555A (en) * 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) * 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) * 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) * 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
HU190072B (en) * 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4977173A (en) * 1987-10-21 1990-12-11 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) * 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
WO1993009103A1 (en) * 1991-11-01 1993-05-13 The Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
US5349045A (en) * 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
DK0623615T3 (da) * 1993-05-01 1999-12-13 Merck Patent Gmbh Adhæsionsreceptor-antagonister
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
KR100441334B1 (ko) * 1995-02-03 2004-10-20 파마시아 앤드 업존 캄파니 헤테로-방향족고리치환된페닐옥사졸리딘온항균제
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
HRP970049A2 (en) * 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2759585B1 (fr) * 1997-02-17 1999-06-11 Sanofi Sa Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique
EP0947196B1 (en) * 1997-03-14 2009-06-17 Toray Industries, Inc. Sustained-release prostaglandin i derivative preparation
US5935724A (en) * 1997-04-04 1999-08-10 Wilson Greatbatch Ltd. Electrochemical cell having multiplate electrodes with differing discharge rate regions
US6218413B1 (en) * 1997-05-30 2001-04-17 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
CA2294293A1 (en) * 1997-07-11 1999-01-21 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
GB9715894D0 (en) * 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
CA2303959A1 (en) * 1997-11-12 1999-05-20 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions
US6083967A (en) * 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
US20010029351A1 (en) * 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
ATE222115T1 (de) * 1998-05-18 2002-08-15 Upjohn Co Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
PE20010851A1 (es) * 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
SK7572002A3 (en) * 1999-12-21 2002-12-03 Upjohn Co Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
KR20020063609A (ko) * 1999-12-28 2002-08-03 아지노모토 가부시키가이샤 아스파탐 유도체 결정
US6514529B2 (en) * 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) * 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110754A1 (de) * 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de) * 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) * 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10134481A1 (de) * 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10152460A1 (de) * 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung

Also Published As

Publication number Publication date
DE102004062475A1 (de) 2006-07-06
MX2007007491A (es) 2007-08-15
EP1830855A1 (de) 2007-09-12
JP2008525335A (ja) 2008-07-17
HN2005036387A (es) 2010-02-01
ZA200704661B (en) 2009-09-30
PL1830855T3 (pl) 2010-07-30
IL184126A0 (en) 2007-10-31
EP1830855B1 (de) 2010-02-24
CN103222969A (zh) 2013-07-31
MY143999A (en) 2011-07-29
DE502005009109D1 (de) 2010-04-08
UA88938C2 (ru) 2009-12-10
US20070026065A1 (en) 2007-02-01
PE20081189A1 (es) 2008-10-16
SI1830855T1 (sl) 2010-05-31
AR052843A1 (es) 2007-04-04
CA2591972A1 (en) 2006-07-13
AU2005324132B2 (en) 2011-04-28
CA2591972C (en) 2012-06-19
JP5285913B2 (ja) 2013-09-11
RU2007127995A (ru) 2009-01-27
DK1830855T3 (da) 2010-06-07
KR20070094631A (ko) 2007-09-20
CY1110649T1 (el) 2012-05-23
RU2420290C2 (ru) 2011-06-10
SV2007002359A (es) 2007-02-16
NO20073853L (no) 2007-09-20
CN101128205A (zh) 2008-02-20
BRPI0519376A2 (pt) 2009-01-20
PT1830855E (pt) 2010-04-27
GT200500384A (es) 2006-11-07
AU2005324132A1 (en) 2006-07-13
ATE458486T1 (de) 2010-03-15
TW200637558A (en) 2006-11-01
WO2006072367A1 (de) 2006-07-13
MA29115B1 (fr) 2007-12-03
NZ556015A (en) 2010-07-30
ES2340053T3 (es) 2010-05-28

Similar Documents

Publication Publication Date Title
PE20061334A1 (es) Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada
AR056564A1 (es) Formas de presentacion farmaceuticas solidas de administracion oral con liberacion rapida del principio activo
AR110413A2 (es) Compuesto 5-cloro-n-((5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-ilmetil)-2-tiofencarboxamida
ECSP066584A (es) Procedimiento para la producción de una composición farmacéutica sólida de administración oral
PE20142292A1 (es) Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus metodos y usos
NO20092636L (no) Ikke-nukleosid-reverstranskriptaseinhibitorer
PE20081228A1 (es) Compuesto heteromonociclico
ECSP14033581A (es) Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
UA97660C2 (ru) Жидкие композиции солей 4-[2-(4-метилфенилсульфанил)фенил]-пиперидина
HK1130252A1 (en) Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
NI200900161A (es) Sales de adición de ácido, hidratos y polimorfos de la etil - amida del ácido 5 - (2,4 -dihidroxi -5- isopropil - fenil) -4- (4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas.
NO20081982L (no) Faste, oralt administrerbare farmasoytiske doseringsformer med rask frigivelse av aktiv forbindelse
DOP2004001034A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente que comprende 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida en forma hidrofilizada
UY29305A1 (es) Formas de dosificación farmacéutica sólidas administrables por vía oral con liberación modificada
CU20070150A7 (es) Formas de dosificacion farmacéutica sólidas administrables por vía oral con liberación modificada
AR062215A1 (es) Inhibidor de trombina activo por via oral
UY28628A1 (es) Procedimiento para la preparación de una composición farmacéutica sólida administrable oralmente
TH93154A (th) รูปแบบยาทางเภสัชกรรมที่เป็นของแข็งซึ่งสามารถให้ได้ทางปาก และมีการปลดปล่อยอย่างรวดเร็วของส่วนประกอบหลัก
DOP2005000265A (es) Forma de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada.
AR082647A1 (es) Composiciones y metodos para tratar sindrome mielodisplasico
TH93154B (th) รูปแบบยาทางเภสัชกรรมที่เป็นของแข็งซึ่งสามารถให้ได้ทางปาก และมีการปลดปล่อยอย่างรวดเร็วของส่วนประกอบหลัก

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed